125 related articles for article (PubMed ID: 37925965)
1. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
[TBL] [Abstract][Full Text] [Related]
2. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
van Maaren MC; van Steenbeek CD; Pharoah PDP; Witteveen A; Sonke GS; Strobbe LJA; Poortmans PMP; Siesling S
Eur J Cancer; 2017 Nov; 86():364-372. PubMed ID: 29100191
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
4. Development of a Prognostic App (iCanPredict) to Predict Survival for Chinese Women With Breast Cancer: Retrospective Study.
Ma Z; Huang S; Wu X; Huang Y; Chan SW; Lin Y; Zheng X; Zhu J
J Med Internet Res; 2022 Mar; 24(3):e35768. PubMed ID: 35262503
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
6. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.
Candido Dos Reis FJ; Wishart GC; Dicks EM; Greenberg D; Rashbass J; Schmidt MK; van den Broek AJ; Ellis IO; Green A; Rakha E; Maishman T; Eccles DM; Pharoah PDP
Breast Cancer Res; 2017 May; 19(1):58. PubMed ID: 28532503
[TBL] [Abstract][Full Text] [Related]
7. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant chemotherapy on survival of women with T1N0M0, hormone receptor negative breast cancer.
Bhoo-Pathy NT; Inaida S; Tanaka S; Taib NA; Yip CH; Saad M; Kawakami K; Bhoo-Pathy N
Cancer Epidemiol; 2017 Jun; 48():56-61. PubMed ID: 28371729
[TBL] [Abstract][Full Text] [Related]
9. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
10. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
11. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
12. Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath.
Karapanagiotis S; Pharoah PDP; Jackson CH; Newcombe PJ
Clin Cancer Res; 2018 May; 24(9):2110-2115. PubMed ID: 29444929
[No Abstract] [Full Text] [Related]
13. Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer.
Deng Z; Jones MR; Wolff AC; Visvanathan K
JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37773987
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
Engelhardt EG; van den Broek AJ; Linn SC; Wishart GC; Rutgers EJT; van de Velde AO; Smit VTHBM; Voogd AC; Siesling S; Brinkhuis M; Seynaeve C; Westenend PJ; Stiggelbout AM; Tollenaar RAEM; van Leeuwen FE; van 't Veer LJ; Ravdin PM; Pharaoh PDP; Schmidt MK
Eur J Cancer; 2017 Jun; 78():37-44. PubMed ID: 28412587
[TBL] [Abstract][Full Text] [Related]
15. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
16. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
17. Validation of the online PREDICT tool in a cohort of early breast cancer in Brazil.
Magário MB; Santos RRD; Teixeira LA; Tiezzi DG; Pimentel FF; Carrara HHA; Andrade JM; Reis FJCD
Braz J Med Biol Res; 2022; 55():e12109. PubMed ID: 36350970
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women.
Dignam JJ
J Natl Cancer Inst Monogr; 2001; (30):36-43. PubMed ID: 11773290
[TBL] [Abstract][Full Text] [Related]
19. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
